retatrutide clinical trials weight loss New GLP-1 obesity drug, retatrutide, shows added benefits Retatrutide For Women: 30% Weight

Reporting suspected side effects is a vital part of medicines safety in the UK, and this principle applies equally to investigational treatments used within clinical trials

The absence of evidence is a critical point

also authorised as Zepbound for weight management, though NHS access for weight management depends on NICE guidance and local commissioning decisions [11] [12] Referral to a Tier 3 or Tier 4 specialist weight management service for more complex cases If you are interested in participating in a clinical trial involving retatrutide or similar investigational medicines, your GP may be able to refer you to a research centre

Chen J, Zhao H, Ma X, Zhang Y, Lu S, Wang Y, et al

Boylan MO, Glazebrook PA, Tatalovic M, Wolfe MM

This action complements the GLP-1 effects and provides additional metabolic benefits, particularly in individuals with insulin resistance or type 2 diabetes